- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03823040
Clinical Assessment of Oxiconazole Nitrate Solid Lipid Nanoparticles Loaded Gel
Oxiconazole Nitrate Solid Lipid Nanoparticles : Formulation, In-vitro Characterization and Clinical Assessment of An Analogous Loaded Carbopol Gel
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The clinical work has been carried out in accordance with The Code of Ethics of the World Medical Association for experiments involving humans. The study was conducted on 28 patients (12 to 50 years old) with tinea of different types attending the dermatology department outpatient clinic of Minia University Hospital. Local institutional review board approval was obtained for this study (ethical approval number is 23/12). Pregnant females and patients with Immunocompromising disease,open wounds and psychological disorders were excluded. Patients were subjected to skin irritation test by applying gel on an area of 2 square inch to the back of hand. Then, examination for the presence of lesion or irritation was conducted. The patients divided into two groups of 14 patients each. Tinox® group was male patients from 12 to 43 years old. The included cases were 5 tinea pedis, 9 tinea versicolor. Oxiconazole nitrate SLNs loaded gel group was 13 males and one female from17 to 50 years old. The included cases were 3 tinea pedis, 8 tinea versicolor, 3 tinea circinate. An informed consent has been obtained from all patients enrolled in the study for photography and treatment. History, general local examination and laboratory investigation for all patients were conducted.The patients were clinically examined after determining the type of infection. Tinox® group was treated with Tinox® cream 1 % while oxiconazole nitrate SLNs loaded gel group was treated with the oxiconazole nitrate SLNs-loaded gel. Treatment was performed by rubbing the cream or gel twice daily for two/ four weeks according to different types of tinea. Patients were advised to avoid sun exposure between 10 am and 4 pm and avoid removal of the applied dose during the period of follow up, the clinical improvement of the patients and length of treatment was assessed according to quartile grading scale patient satisfaction. It was rated by the patient and the physician as excellent, good, fair and poor according to the following criteria. Excellent: both the patient and the physician agreed that the result was satisfactory. Good: the result although acceptable was not quite up to expectation of the patient, but the physicians were pleased with the outcome. Fair: the improvement was evaluated by both the patient and the physician to be less than expected but still with same improvement. Poor: unsatisfactory results to the patient and /or the physician. All adverse effects were checked during study.High resolution digital photographs were taken for lesions of all patients using identical camera folder setting before starting and one-month post treatment. Clinical improvement was evaluated by physicians through comparing photographs. The criteria for evaluations using a quartile grading scale was: 0=no improvement. 1=mild (percent improvement, less than 25%), 2=moderate (percent improvement 25-49%), 3=good (percent improvement 50-74%), 4=excellent (percent improvement more than 75%). In addition, a patient satisfaction score was rated using the following scale, A. not satisfied, B. somewhat satisfied, C. highly satisfied.
Skin scrapes were taken from each group before and after treatment. All skin scrapes were routinely processed by potassium hydroxide 20% to be examined for presence of fungal elements. A built-in camera and a light microscope were used to photograph and examine the sectioned skin areas.
IBM SPSS® ( International business machine statistical Package for the Social Sciences (version 22, USA) was utilised for data analysis. The acceptability of the tested formulations was assessed using the chi-square test, P ≤ 0.05 was considered statistically significant. All the results were presented as the mean ± standard deviation (SD).
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Minya, Egypt, 61519
- Minia University Hospital,dermatology department, out patient clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients with different types of tine infection
Exclusion Criteria:
- Pregnant females and patients with Immunocompromising disease, open wounds and psychological disorders were excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Tinox® group
Male patients (12 to 43 years old) including 5 cases tinea pedis, 9 tinea versicolor and treated with oxiconazole nitrate cream 1%.
|
Tinox® group was treated with oxiconazole nitrate cream 1 % .
Treatment was performed by rubbing the cream twice daily for two/ four weeks according to different types of tinea.
Other Names:
|
Experimental: Oxiconazole nitrate SLNs loaded gel group
13 males and one female (17 to 50 years old) including 3 cases tinea pedis, 8 tinea versicolor, 3 tinea circinate and treated with oxiconazole nitrate SLNs loaded gel
|
Oxiconazole nitrate SLNs loaded gel group was treated with oxiconazole nitrate SLNs loaded gel.Treatment was performed by rubbing the gel twice daily for two/ four weeks according to different types of tinea.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of clinical improvement using quartile grading scale patient satisfaction
Time Frame: one month
|
the clinical improvement of the patients was assessed according to quartile grading scale patient satisfaction.
It was rated by the patient and the physician as excellent, good, fair and poor according to the following criteria.
Excellent: both the patient and the physician agreed that the result was satisfactory.
Good: the result although acceptable was not quite up to expectation of the patient, but the physicians were pleased with the outcome.
Fair: the improvement was evaluated by both the patient and the physician to be less than expected but still with same improvement.
Poor: unsatisfactory results to the patient and /or the physician.
All adverse effects were checked during study.
|
one month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Microscopical examination of skin scrapes for detection of fungal elements
Time Frame: one month
|
Skin scrapes were taken from each group before and after treatment.
All skin scrapes were routinely processed by potassium hydroxide 20% to be examined for presence of fungal elements.
A built-in camera and a light microscope were used to photograph and examine the sectioned skin areas.
|
one month
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Heba F Mansour, Ph.D, Associate professor of Pharmaceutics, Faculty of Pharmacy, Minia and Deray University, Minia, Egypt.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OXIHebaSLNs
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tinea
-
National institute of SiddhaCompletedTinea Infections Such as Tinea Corporis, Tinea Cruris, Tinea Pedis, Tinea Mannum, Tinea Barbae, Tinea Capitis Are StudiedIndia
-
Dhaka Medical CollegeNot yet recruitingTinea Cruris | Tinea Corporis | Dermatophytoses | Tinea Faciei
-
Tinea PharmaceuticalsCompletedTinea Pedis | Tinea Cruris | Tinea CorporisUnited States, Puerto Rico, El Salvador, Belize, Honduras
-
Laboratório Teuto Brasileiro S/AUnknownTinea Pedis | Tinea Cruris | Fungal Infections | Tinea CorporisBrazil
-
Therapeutics, Inc.CompletedTinea Pedis | Tinea CrurisUnited States
-
Bausch & Lomb IncorporatedBausch Health Americas, Inc.CompletedTinea Pedis | Tinea CrurisUnited States
-
Bausch Health Americas, Inc.CompletedTinea Pedis | Tinea CrurisDominican Republic, Honduras
-
Merz North America, Inc.CompletedTinea Pedis | Tinea CrurisHonduras, United States, Dominican Republic
-
Medicis Global Service CorporationCompletedTinea CrurisUnited States, Puerto Rico, Honduras, El Salvador, Belize
-
Galeno Desenvolvimento de Pesquisas ClínicasBiolab Sanus FarmaceuticaCompleted
Clinical Trials on Oxiconazole Nitrate Cream 1%
-
Taro Pharmaceuticals USACompleted
-
AmDermaCompleted
-
Padagis LLCCompletedVulvovaginal CandidiasisUnited States
-
Jamaica Hospital Medical CenterJohnson & JohnsonUnknownTinea Pedis | Athlete's Foot | Foot Fungus | RingwormUnited States
-
AmDermaAmDerma Pharmaceuticals, LLCCompletedTinea Pedis | Athlete's FootUnited States
-
Dermavant Sciences GmbHCompletedAtopic DermatitisUnited States, Canada
-
Dermavant Sciences GmbHCompletedAtopic DermatitisUnited States, Canada
-
GlaxoSmithKlineCompletedDermatitis, AtopicUnited States, Canada, Japan
-
GlaxoSmithKlineCompletedPsoriasisUnited States, Canada, Japan
-
Aziende Chimiche Riunite Angelini Francesco S.p.ACross Research S.A.Completed